TEC Inhibitors
1 drugsAbout TEC
TEC (tyrosine kinase expressed in hepatocellular carcinoma) is a non-receptor tyrosine kinase involved in intracellular signaling pathways. Its role in these pathways makes it a potential point of therapeutic intervention.
Currently, there is no genetic evidence directly linking TEC to specific diseases. However, the presence of an approved drug suggests potential for therapeutic intervention.
TEC is targeted by one FDA-approved drug, RHAPSIDO, a small molecule. Novartis is the sole company with an approved drug for this target, indicated for 'other' therapeutic areas.
Top TEC Drugs
Novartis is the only company with an approved drug targeting TEC.
Low competition may present an opportunity, but also signals potential challenges in the target's viability.
TEC Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TEC, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
TEC Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TEC. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 3 | 0 | 1 | 2 | 0% |
| Phase 3 | 16 | 0 | 0 | 16 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved TEC drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting TEC. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
TEC Drug Approval Timeline (2025 - 2025)
The first and most recent drug approval for TEC was RHAPSIDO in 2025.
The recent approval suggests renewed interest, but further approvals are needed to confirm sustained viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TEC. A trial counts if an approved drug acting on TEC is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.